1. Home
  2. NRIX vs NWN Comparison

NRIX vs NWN Comparison

Compare NRIX & NWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$15.10

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

NWN

Northwest Natural Holding Company

HOLD

Current Price

$52.10

Market Cap

2.1B

Sector

Utilities

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRIX
NWN
Founded
2009
1859
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil/Gas Transmission
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.1B
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
NRIX
NWN
Price
$15.10
$52.10
Analyst Decision
Strong Buy
Buy
Analyst Count
13
2
Target Price
$29.46
$52.50
AVG Volume (30 Days)
706.3K
245.3K
Earning Date
05-01-2026
01-01-0001
Dividend Yield
N/A
3.78%
EPS Growth
N/A
36.45
EPS
N/A
2.77
Revenue
$76,987,000.00
$1,289,363,000.00
Revenue This Year
N/A
$8.97
Revenue Next Year
$26.32
$4.27
P/E Ratio
N/A
$18.79
Revenue Growth
99.31
11.83
52 Week Low
$8.18
$38.94
52 Week High
$22.50
$53.66

Technical Indicators

Market Signals
Indicator
NRIX
NWN
Relative Strength Index (RSI) 37.80 65.85
Support Level $11.34 $45.72
Resistance Level $16.49 N/A
Average True Range (ATR) 0.76 1.29
MACD 0.02 0.14
Stochastic Oscillator 24.87 67.00

Price Performance

Historical Comparison
NRIX
NWN

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About NWN Northwest Natural Holding Company

Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in one reportable business segment, which is NW Natural's local gas distribution business and is referred to as the NGD segment. The company generates its revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.

Share on Social Networks: